All News

Combining medical, rehab, psychological, and complementary therapies offers more person-centered relief for chronic pain.

Emily Eddy, PharmD, BCACP, BC-ADM, CDCES, presents on the ever-expanding world of glucagon-like peptide-1s, now heading toward indications for chronic kidney disease and substance use disorder.

Pharmacists face alarming burnout rates, but hobbies—from horses to sports—can help protect mental health and keep patient care safer.

Local pharmacies deliver rapid flu, COVID-19, strep, and urinary tract infection tests with same-day treatment, easing access gaps and cutting urgent care costs.

Investigators of the multicenter cohort aim to determine if the 13-valent pneumococcal conjugate vaccine impacted disease activity over a 24-month period.

A growing body of evidence suggests that the choice of glucose-lowering therapy may play a critical role in colorectal cancer prevention.

Ulcers represent one of the most serious and costly complications of diabetes characterized by a high risk of recurrence.

Benjamin Jolley, PharmD, presents on recent developments regarding pharmacy benefit manager reform on the state and federal levels.

TrumpRx offers discounted cash drug prices like a coupon card but skips PBM reform and raises concerns about deductible gaps and added pressure on independent pharmacies.

Wounds are defined as disruptions of tissue integrity that can occur in the skin, mucous membranes, or internal organs, often accompanied by pain and infection risks.

Travis Wolff, PharmD, BCACP, presents on the current landscape of medical billing in pharmacy practice and the steps pharmacists can take to realize a significantly higher profit margin.

Independent pharmacies boost retention with clear hiring expectations, structured onboarding, weekly check-ins, and real growth opportunities.

Pharmacists boost chronic disease outcomes by adding quick nutrition screening, counseling, and drug-nutrient checks to everyday visits.

Orforglipron is the first new molecular entity to be cleared under the FDA Commissioner's National Priority Voucher pilot program.

In part 2, Sylvie Stacy, MD, MPH, explores the current evidence regarding GLP-1s for SUD, the work still necessary in the future of this space, and where pharmacists fall within it all.

This issue discusses independent pharmacies retaining talent, navigating TrumpRx and MFN drug pricing shifts, and confronting pharmacy benefit manager power to protect community care.

The intersection of nutrition and pharmacy is a critical, yet often underutilized, frontier in modern health care.

This study indicates that stopping the medication is noninferior to continuing it indefinitely in terms of preventing death, recurrent heart attacks, or hospitalizations.

This benefit was primarily driven by significant reductions in nonfatal heart attacks and the need for revascularization procedures.

The study demonstrated that providing a combination of produce prescriptions, dietitian coaching, and artificial intelligence-optimized encouragement led to improved cardiovascular outcomes.

The biosimilar is approved for all indications of the reference product, including the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Ashley Chinchilla, PharmD, BCACP, presents on the persistence of vaccine hesitancy among patients and the powerful tools used to address it.

As population-level introduction of pneumococcal conjugate vaccines has led to an increase in invasive disease, the development of higher-valency vaccines has become a primary solution.

Stefanie Ferreri, PharmD, BCACP, FCCP, FAPhA, presents on the increase of misinformation circulating among the public and how pharmacists can combat this phenomenon.

Susan Cornell, PharmD, CDCES, FAPhA, FADCES, and Staci-Marie Norman, PharmD, CDCES, FAPhA, present on updates to the ADA Standards of Care in Diabetes.

Serotype 19F resurges despite PCVs, raising invasive disease risk in older adults; pharmacists track immune evasion, variants, and boost adherence.

The FDA approves removing the age requirement for epinephrine nasal spray (neffy) 1 mg, effectively allowing all children and adults who weigh 33 pounds.

These guidelines serve as a comprehensive guideline that prioritizes earlier intervention through lifestyle optimization and lower treatment targets for those at highest risk.